Supplements vergleichen

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Any time

Subkutane Injektion einmal täglich (Victoza bei Diabetes, Saxenda zur Gewichtskontrolle)

INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.

Any time

Orale Tablette (experimentell)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity to liraglutide or any GLP-1 receptor agonist

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Not an approved medicine — only appropriate within a clinical trial or, if/when approved, under a clinician
• Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern
• History of pancreatitis (caution, consistent with the GLP-1 class)

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists